4.7 Review

Gout: why is this curable disease so seldom cured?

期刊

ANNALS OF THE RHEUMATIC DISEASES
卷 71, 期 11, 页码 1765-1770

出版社

BMJ PUBLISHING GROUP
DOI: 10.1136/annrheumdis-2012-201687

关键词

-

资金

  1. Menarini Group
  2. Ardea Biosciences
  3. Ipsen
  4. Menarini
  5. Novartis
  6. Savient
  7. Abbott
  8. Roche
  9. UCB
  10. Biocryst
  11. Fidia
  12. Merck
  13. Pfizer

向作者/读者索取更多资源

Gout is the most common inflammatory arthritis and one in which pathogenesis and risk factors are best understood. One of the treatment objectives in current guidelines is 'cure'. However, audits show that only a minority of patients with gout receive adequate advice and treatment. Suboptimal care and outcomes reflect inappropriately negative perceptions of the disease, both in patients and providers. Historically, gout has been portrayed as a benign and even comical condition that is self-inflicted through overeating and alcohol excess. Doctors often focus on managing acute attacks rather than viewing gout as a chronic progressive crystal deposition disease. Urate-lowering treatment is underprescribed and often underdosed. Appropriate education of patients and doctors, catalysed by recent introduction of new urate-lowering treatments after many years with no drug development in the field, may help to overcome these barriers and improve management of this easily diagnosed and curable form of potentially severe arthritis.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据